knowledge -WSS

knowledge

author：comprehensive 2025-10-01 11:02:37 - browse：7

Why are rich biotechs cutting costs? Has JPM Week already worn off? And what’s going to move markets in 2024?

We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. Our colleague Jason Mast joins us to discuss an emerging trend in biotech: Cash-rich startups are laying off employees and tweaking their strategies amid a tough market for venture capital. We also look ahead to the biggest biotech stories coming in 2024, including some major data readouts and a few pivotal FDA decisions.

For more on what we cover, here’s the news on Dewpoint Therapeutics; here’s more on biotech in 2024; here’s where you can find episodes of Color Code; here’s where you can subscribe to the First Opinion Podcast; and here’s where you can subscribe to our biotech newsletter, The Readout.

Be sure to sign up on Apple Podcasts, Spotify, Stitcher, TuneIn, or wherever you get your podcasts.

And if you have any feedback for us — topics to cover, guests to invite, vocal tics to cease — you can email [email protected].

Previous article： Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen
Next article： Amazon expands telehealth clinic nationwide

leisure time

hotspot

WSS

Physician groups backed by private equity giant lobby on mergers

Pence says 'crackpot lawyers' told Trump what he wanted to hear

Breakthrough Alzheimer’s drugs are inaccessible in rural states

Tire on Delta flight pops while landing in Atlanta, 1 person injured, airline says

Surgeons perform first xenotransplant using CRISPR'd pig kidney

Wildfire pollution widens asthma inequities on Long Island

entertainment

knowledge

hotspot

Jerome Adams on the need for new antivirals for Covid

5 important ways Henrietta Lacks changed medical science

United colonoscopy coverage change 'may cost lives,' doctors say

U.K. officials, researchers try to ease path for bespoke genetic treatments

Walensky prepares to leave CDC — and Congress — behind

Listen: Biogen's situation, Wegovy's risks, & biotech insider trading

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Lawsuit alleges UnitedHealth Group unit illegally denied claims

Malaria cases in Florida and Texas: Here’s what you need to know

Cancer, immunology, HIV research ensnared in fetal tissue politics

hotspot

Chinese researcher claims birth of first gene

Scientists inch closer to single

Physician groups backed by private equity giant lobby on mergers

EQRx, failed developer of low

NIH launches clinical trials and new research office for long Covid

Pence says 'crackpot lawyers' told Trump what he wanted to hear

leisure time

hotspot

Wikipedia

entertainment